Skip to main content
Erschienen in: Strahlentherapie und Onkologie 6/2014

01.06.2014 | Original article

Evaluation of time, attendance of medical staff and resources for radiotherapy in pediatric and adolescent patients

The DEGRO-QUIRO trial

verfasst von: Prof. Dr. Angelika Zabel-du Bois, Prof. Dr. Stefanie Milker-Zabel, Dr. Frank Bruns, Prof. Dr. Hans Christiansen, Dr. Iris Ernst, Prof. Dr. Normann Willich, Dr. Wolfgang Popp, Prof. Dr. Dr. Jürgen Debus, Prof. Dr. Horst Sack

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The German Society of Radiation Oncology (DEGRO) initiated a multicenter trial to develop and evaluate adequate modules to assert core procedures in radiotherapy. The aim of this prospective evaluation was to methodical assess the required resources for radiotherapy in pediatric and adolescent patients.

Material and methods

At three radiotherapy centers of excellence (University Hospitals of Heidelberg and Münster, the Medical School of Hannover), the manpower and time required for radiotherapy in pediatric and adolescent patients was prospectively documented consistently over a 2-year period. The data were collected using specifically developed standard forms and were evaluated using specific process analysis tools.

Results

A total number of 1914 data sets were documented and carefully analyzed. The personnel time requirements for all occupational groups were calculated as total time needed for a specific procedure and mean time per person. Regarding radiotherapy in general anesthesia, the required manpower was higher. The personnel time requirements in these cases were also longer, mainly due to longer room occupancy. Overall, the required resources were remarkably similar between the three different departments and may, therefore, be considered as representative.

Conclusion

For the first time, the personnel time requirements of a radiotherapy department for the maintenance, protection, and optimization of operational readiness for radiotherapy in pediatric and adolescent patients with and without general anesthesia were determined methodically.
Literatur
1.
Zurück zum Zitat Bentzen SM, Heeren G, Cottier B et al (2005) Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75:355–365PubMedCrossRef Bentzen SM, Heeren G, Cottier B et al (2005) Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75:355–365PubMedCrossRef
2.
Zurück zum Zitat Bernier J, Horiot JC, Bartelink H et al (1996) Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 34:953–960PubMedCrossRef Bernier J, Horiot JC, Bartelink H et al (1996) Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 34:953–960PubMedCrossRef
3.
Zurück zum Zitat Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. The DEGRO-QUIRO trial. Strahlenther Onkol 188:113–119PubMedCrossRef Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. The DEGRO-QUIRO trial. Strahlenther Onkol 188:113–119PubMedCrossRef
4.
Zurück zum Zitat Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: The DEGRO-QUIRO trial. Strahlenther Onkol 187:449–460PubMedCrossRef Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: The DEGRO-QUIRO trial. Strahlenther Onkol 187:449–460PubMedCrossRef
5.
Zurück zum Zitat De Braganca KC, Packer RJ (2013) Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). Curr Treat Options Neurol 15:593–606 De Braganca KC, Packer RJ (2013) Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). Curr Treat Options Neurol 15:593–606
6.
Zurück zum Zitat Esco R, Palacios A, Pardo J et al (2003) Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources. Int J Radiat Oncol Biol Phys 56:319–327PubMedCrossRef Esco R, Palacios A, Pardo J et al (2003) Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources. Int J Radiat Oncol Biol Phys 56:319–327PubMedCrossRef
7.
Zurück zum Zitat Fietkau R, Budach W, Zamboglou N et al (2012) Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO-QUIRO trial. Strahlenther Onkol 188:5–11PubMedCrossRef Fietkau R, Budach W, Zamboglou N et al (2012) Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO-QUIRO trial. Strahlenther Onkol 188:5–11PubMedCrossRef
8.
Zurück zum Zitat Fortney JT, Halperin EC, Hertz CM, Schulman SR (1999) Anesthesia for pediatric external beam radiation therapy. Int J Radiat Oncol Biol Phys 44:587–591PubMedCrossRef Fortney JT, Halperin EC, Hertz CM, Schulman SR (1999) Anesthesia for pediatric external beam radiation therapy. Int J Radiat Oncol Biol Phys 44:587–591PubMedCrossRef
9.
Zurück zum Zitat Horiot JC, Johansson KA, Gonzales DG et al (1986) Quality assurance control in the EORTC Cooperative Group of Radiotherapy. 1: Assessment of radiotherapy staff and equipment. Radiother Oncol 6:275–284PubMedCrossRef Horiot JC, Johansson KA, Gonzales DG et al (1986) Quality assurance control in the EORTC Cooperative Group of Radiotherapy. 1: Assessment of radiotherapy staff and equipment. Radiother Oncol 6:275–284PubMedCrossRef
10.
Zurück zum Zitat Kaste SC, Dome JS, Babyn PS et al (2008) Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatr Radiol 38:2–17PubMedCrossRef Kaste SC, Dome JS, Babyn PS et al (2008) Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatr Radiol 38:2–17PubMedCrossRef
11.
12.
Zurück zum Zitat Ruggieri-Pignon S, Pignon T, Marty M et al (2005) Infrastructure of radiation oncology in France: a large survey of evolution of external beam radiotherapy practice. Int J Radiat Oncol Biol Phys 61:507–516PubMedCrossRef Ruggieri-Pignon S, Pignon T, Marty M et al (2005) Infrastructure of radiation oncology in France: a large survey of evolution of external beam radiotherapy practice. Int J Radiat Oncol Biol Phys 61:507–516PubMedCrossRef
13.
Zurück zum Zitat Slotman BJ, Cottier B, Bentzen SM et al (2005) Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol 75:349–354PubMedCrossRef Slotman BJ, Cottier B, Bentzen SM et al (2005) Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol 75:349–354PubMedCrossRef
14.
Zurück zum Zitat Terezakis SA, Wharam MD (2013) Radiotherapy for rhabdomyosarcoma: indications and outcome. Clin Oncol (R Coll Radiol) 25:27–35CrossRef Terezakis SA, Wharam MD (2013) Radiotherapy for rhabdomyosarcoma: indications and outcome. Clin Oncol (R Coll Radiol) 25:27–35CrossRef
15.
Zurück zum Zitat van Daal WAJ, Bos MA (1997) Infrastructure for radiotherapy in The Netherlands: development from 1970 to 2010. Int J Radiat Oncol Biol Phys 37:411–415PubMedCrossRef van Daal WAJ, Bos MA (1997) Infrastructure for radiotherapy in The Netherlands: development from 1970 to 2010. Int J Radiat Oncol Biol Phys 37:411–415PubMedCrossRef
16.
Zurück zum Zitat Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery: QUIRO-DEGRO Trial. Strahlenther Onkol 188:769–776PubMedCrossRef Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery: QUIRO-DEGRO Trial. Strahlenther Onkol 188:769–776PubMedCrossRef
Metadaten
Titel
Evaluation of time, attendance of medical staff and resources for radiotherapy in pediatric and adolescent patients
The DEGRO-QUIRO trial
verfasst von
Prof. Dr. Angelika Zabel-du Bois
Prof. Dr. Stefanie Milker-Zabel
Dr. Frank Bruns
Prof. Dr. Hans Christiansen
Dr. Iris Ernst
Prof. Dr. Normann Willich
Dr. Wolfgang Popp
Prof. Dr. Dr. Jürgen Debus
Prof. Dr. Horst Sack
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 6/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0619-z

Weitere Artikel der Ausgabe 6/2014

Strahlentherapie und Onkologie 6/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.